Glenmark Pharmaceuticals has filed a statement of claim with the American Arbitration Association against Napo Pharmaceuticals Inc seeking a declaration that Glenmark’s distribution rights to develop, commercialize and distribute Croferlemer in 140 countries for treatment of diarrhoel diseases includes the exclusive rights to distribute through relief agencies in these countries. The company in order to prevent Napo from distributing products into Glenmark's Territories has filed the case.
Croferlemer is a novel, first in class anti-diarrhoeal agent that has a physcological mechanism of action that is different compared to traditional anti- diarrhoeal agents. Besides, its potential efficacious role in multiple diarrhoeal agents, Croferlemer controls diarrhea with no known drug-drug interaction, minimal systemic adsorption and, unlike, current anti-diarrhoeal agents. No serious side effects, and can be used chronically.
The company has an exclusive license from Napo to develop, commercialize and distribute Croferlemer in 140 countries for specific indications.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1846.95 |
Dr. Reddys Lab | 1350.65 |
Cipla | 1490.55 |
Lupin | 2357.75 |
Zydus Lifesciences | 961.75 |
View more.. |